Short Interest in Bone Biologics Co. (NASDAQ:BBLG) Rises By 48.2%

Bone Biologics Co. (NASDAQ:BBLG) was the recipient of a large increase in short interest in February. As of February 28th, there was short interest totalling 193,300 shares, an increase of 48.2% from the February 13th total of 130,400 shares. Based on an average daily volume of 218,900 shares, the days-to-cover ratio is presently 0.9 days. Currently, 36.2% of the company’s stock are short sold.

Bone Biologics Stock Performance

Bone Biologics stock opened at $0.83 on Friday. The stock’s 50 day moving average is $0.99 and its 200 day moving average is $1.27. Bone Biologics has a twelve month low of $0.71 and a twelve month high of $4.25.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.